Search - tctmd.com

Displaying 101 - 118 of 118

Sort: Relevancy | Date

Stop the Debate! Selective Use of BMS Is Rational and Cost-Effective

Presentation TCT 2013

Stop the Debate! Selective Use of BMS Is Rational and Cost-Effective

Presenter: David Cohen

October 28, 2013

Transradial Intervention in STEMI: How Long Can We Delay Door-to-Balloon Time?

Presentation TCT 2013

Transradial Intervention in STEMI: How Long Can We Delay Door-to-Balloon Time?

Presenter: David Cohen

October 28, 2013

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

Presentation TCT 2013

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

Presenter: David Cohen

October 28, 2013

A Synthesis of the Global Literature on TAVR Cost-effectiveness

Presentation TCT 2013

A Synthesis of the Global Literature on TAVR Cost-effectiveness

Presenter: David Cohen

October 28, 2013

Predictors of Vascular complications in patients undergoing Balloon Aortic Valvuloplasty

Presentation TCT 2013

Predictors of Vascular complications in patients undergoing Balloon Aortic Valvuloplasty

Presenter: Annapoorna Kini, Roxana Mehran, Nilusha Gukathasan, Ziad Sergie, Mauricio Cohen, Jennifer Yu, Usman Baber, Samantha Sartori, Robert Pyo, Kleanthis Theodoropoulos, Roja Thapi, Elliot Elias, Socrates Kakoulides, Evan Jocobs, David knopf, Jason Kovacic, Raj Vadde, Brian O'Neill, Samin Sharma, George Dangas

January 31, 2013

Cost Effectiveness of the MitraClip® Compared with Mitral Valve Surgery: 12-month Results from the EVEREST II Randomized Controlled Trial

Presentation TCT 2013

Cost Effectiveness of the MitraClip® Compared with Mitral Valve Surgery: 12-month Results from the EVEREST II Randomized Controlled Trial

Presenter: Matthew Reynolds, Benjamin Galper, Patricia Apruzzese, Joshua Walczak, Laura Mauri, Ted Feldman, Donald Glower, David Cohen

January 31, 2013

A Stepwise Approach to Building a Career in Interventional Cardiology Research

Presentation TCT 2012

A Stepwise Approach to Building a Career in Interventional Cardiology Research

Presenter: David Cohen

October 25, 2012

Personalized Medicine: Current Tools and the Future of Clinical Research in Practice

Presentation TCT 2012

Personalized Medicine: Current Tools and the Future of Clinical Research in Practice

Presenter: David Cohen

October 22, 2012

News Conference News TCT 2012

PARTNER Analyses Provide Important Insights into TAVR

October 22, 2012

Lessons from the Quality-of-Life Studies in Inoperable and High-Risk Patients

Presentation TCT 2012

Lessons from the Quality-of-Life Studies in Inoperable and High-Risk Patients

Presenter: David Cohen

October 22, 2012

An Introduction to Cost-Effectiveness Analyses: Who Pays (and Should They)?

Presentation TCT 2012

An Introduction to Cost-Effectiveness Analyses: Who Pays (and Should They)?

Presenter: David Cohen

October 22, 2012

News Conference News

PARTNER A: Transfemoral TAVR Improved QOL, Costs vs. Surgery

November 09, 2011

Video

» Conference Wrap-Up

TCT 2024 Day 2 Wrap-Up

October 28, 2024

Video

» Interview

TCT 2019 Deep Dive With Dr. C. Michael Gibson and Dr. David Cohen

September 29, 2019

Video

» Interview

TCT 2018: Dr. C. Michael Gibson talks with Dr. David Cohen about quality of life in the COAPT study: Adding years to life and adding life to years

September 24, 2018

Video

» Interview

TCT 2017: Dr. C. Michael Gibson talks with Dr. David Cohen about PARTNER 2A and SAPIEN 3 Cost-effectiveness

May 11, 2018

Video

» Interview

Late Breaking Clinical Trial Interview: PARTNER II QUALITY OF LIFE: David J. Cohen, MD

May 11, 2018

Video

» Interview

TCT 2016: Dr. C. Michael Gibson talks with Dr. David Cohen about PARTNER II QUALITY OF LIFE

May 11, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.